Format

Send to

Choose Destination
Obstet Gynecol Clin North Am. 2019 Mar;46(1):37-53. doi: 10.1016/j.ogc.2018.09.003.

Germline and Somatic Tumor Testing in Gynecologic Cancer Care.

Author information

1
University of California, Irvine, 333 The City Boulevard, Suite 1400, Orange, CA 92868, USA. Electronic address: jalldred@uci.edu.
2
University of California, Irvine, 333 The City Boulevard, Suite 1400, Orange, CA 92868, USA.

Abstract

New technologies have advanced the science of tumor biology and genomics. Commercially available germline and somatic testing modalities have the downstream benefits of enabling prevention strategies in women with hereditary cancers and their family members in addition to identifying women who benefit most from novel targeted therapeutics. The matrix of available testing is complex and evolving. Women's health providers need to be versed in benefits and limitations of available testing. Genetic counselors play a pivotal role in interpretation of relevant mutations, and in avoiding common pitfalls, but their skill set is not sufficient to optimally integrate cancer genomics into clinical practice.

KEYWORDS:

Genomics; Germline; Gynecologic cancer; Somatic; Tumor testing

PMID:
30683265
DOI:
10.1016/j.ogc.2018.09.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center